Jump to content

Pamrevlumab

Edit links
From Wikipedia, the free encyclopedia

This is an old revision of this page, as edited by WikiCleanerBot (talk | contribs) at 00:38, 5 January 2021 (v2.04b - Bot T20 CW#61 - Fix errors for CW project (Reference before punctuation)). The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.

Pamrevlumab
Monoclonal antibody
Type?
SourceHuman
TargetCTGF
Clinical data
Other namesFG-3019
ATC code
  • none
Identifiers
CAS Number
ChemSpider
  • none
UNII
KEGG
Chemical and physical data
FormulaC6492H10018N1718O2086S48
Molar mass147050.38 g·mol−1

Pamrevlumab (INN;[1] development code FG-3019) is a humanized monoclonal antibody designed for the treatment of idiopathic pulmonary fibrosis and pancreatic cancer.

This drug was developed by FibroGen, Inc.[2]

References

  1. ^ World Health Organization (2015). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 113" (PDF). WHO Drug Information. 29 (2).
  2. ^ Statement On A Nonproprietary Name Adopted By The USAN Council - Pamrevlumab, American Medical Association.
Stub icon

This monoclonal antibody–related article is a stub. You can help Wikipedia by expanding it.

Retrieved from "https://en.wikipedia.org/w/index.php?title=Pamrevlumab&oldid=998355121"